Biogen (BIIB) Stock Highlights

199.46 | +1.96%

2024-09-16 19:53:49

Biogen and Idec merged in 2003, combining forces to market Biogens multiple sclerosis drug Avonex and Idecs cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogens MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firms first Alzheimers disease therapy in June 2021.

Statistics

Range Today

194.75 199.59

Volume Today 608.33K

Range 1 Year

189.44 269.43

Volume 1 Year 271.07M

Range 3 Year

187.16 319.76

Volume 3 Year 868.24M

Range 10 Year

187.16 480.18

Volume 10 Year 3.92B

Highlights

Market Capitalization 28.5B (large)

Floating Shares 145.13M

Current Price 199.46

Price To Earnings 24.93

Price To Revenue 3.44

Price To Book 1.79

Earnings Per Share 7.93

Payout Ratio 0%

Performance

Latest +1.96%

1 Month -1.25%

3 Months -13.59%

6 Months -9.48%

1 Year -21.76%

3 Years -33.69%

5 Years -15.54%

10 Years -37.56%

Benchmarks

Market Capitalization

11 / 14

Gross Profits

11 / 14

Total Revenue

11 / 14

Total Rank

2 / 14

Free Cashflow

10 / 14

Performance 5 years

10 / 14

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.